Table 1. Clinical, pathological and molecular findings in 30 cases of GBM.
| Case | Age/Sex | Location | Size (cm) | Treatment | Survival (months) | Ki-67 (%) | EGFR expression | Pattern of infiltration | miR-200c 2-ΔΔCt | EGFR wild/mutant |
| 1 | 72/F | F | 6.0 | RT+CH | 8 | 14.4 | 3 | Diffuse | 0.38 | EGFRvIII |
| 2 | 63/F | T | 7.0 | RT+CH | 11 | 8.5 | 3 | Diffuse | 0.06 | EGFRvIII |
| 3 | 69/M | T | 6.0 | NONE | 6 | 10.4 | 3 | Diffuse | 0.26 | EGFRvIII |
| 4 | 48/M | T | 5.3 | RT+CH | 9 | 10.0 | 3 | Not established | 0.19 | EGFRvIII |
| 5 | 55/F | CC | 4.0 | QT | 4 | 14.0 | 3 | Diffuse | 0.60 | EGFRvIII |
| 6 | 58/F | T | 6.0 | RT+CH | 23 | 21.8 | 3 | Diffuse | 0.12 | EGFRvIII |
| 7 | 61/M | T | 8.0 | RT+CH | 11 | 1.6 | 2 | Not established | 0.26 | EGFRvIII |
| 8 | 59/F | P | 1.5 | RT+CH | 27 | 4.5 | 3 | Diffuse | na | EGFRwt |
| 9 | 66/M | P | 4.0 | RT+CH | 6 | 19.7 | 2 | Not established | 0.17 | EGFRwt |
| 10 | 55/M | P | 6.0 | RT+CH | 10 | 3.8 | 2 | Diffuse | 0.46 | EGFRvIII |
| 11 | 69/M | T | 6.0 | RT+CH | 13 | 50.0 | 2 | Diffuse | 0.29 | EGFRwt |
| 12 | 66/M | P | 3.0 | NONE | ? | 10.1 | 3 | Diffuse | 0.30 | EGFRvIII |
| 13 | 61/F | F | 4.7 | NONE | 2 | 22.4 | 3 | Diffuse | 0.69 | EGFRvIII |
| 14 | 45/M | P | 6.0 | RT+CH | 14 | 0.4 | 1 | Not established | 0.65 | EGFRwt |
| 15 | 24/M | T | 2.5 | NONE | ? | 13.0 | 1 | Not established | 1.44 | EGFRwt |
| 16 | 67/M | T | 7.0 | RT+CH | 9 | 33.5 | 0 | Diffuse | 0.57 | EGFRwt |
| 17 | 73/M | P | 5.0 | RT+CH | 3 | 19.9 | 0 | Diffuse | 1.33 | EGFRwt |
| 18 | 45/M | P | 2.5 | RT+CH | 12 | 6.8 | 2 | Diffuse | 1.02 | EGFRwt |
| 19 | 60/M | P | 4.0 | NONE | 5 | 0.8 | 1 | Nodular | 0.65 | EGFRwt |
| 20 | 72/F | P | 3.7 | RT+CH | 30* | 0.0 | 1 | Nodular | 1.95 | EGFRvIII |
| 21 | 66/F | F | 6.0 | NONE | 2 | 5.1 | 1 | Diffuse | 1.49 | EGFRwt |
| 22 | 66/M | T | 4.0 | RT+CH | 22 | 6.1 | 0 | Diffuse | 0.83 | EGFRwt |
| 23 | 63/M | F | 4.0 | RT+CH | 36 | 23.0 | 0 | Diffuse | 0.63 | EGFRwt |
| 24 | 74/M | O | 4.0 | RT+CH | 13 | 49.7 | 2 | Nodular | 1.21 | EGFRwt |
| 25 | 60/M | F | 4.0 | CH | 18 | 3.0 | 1 | Nodular | 0.93 | EGFRwt |
| 26 | 55/M | F | 6.6 | CH | 27 | 0.8 | 0 | Nodular | 1.02 | EGFRwt |
| 27 | 75/M | O | 4.0 | NONE | 6 | 0.2 | 1 | Diffuse | 1.18 | EGFRwt |
| 28 | 74/M | F | 6.7 | RT+CH | 1 | 10,5 | 1 | Nodular | 1.12 | EGFRwt |
| 29 | 63/F | P | 8.0 | RT | ? | 0.1 | 0 | Diffuse | 1.06 | EGFRwt |
| 30 | 67/M | P | 3.5 | RT+CH | 50* | 7.5 | 0 | Diffuse | na | EGFRwt |
Cases 1–13: High level of EGFR amplification; cases 14–20: Low level of EGFR amplification; cases 21–30: no EGFR amplification. Sex: male (M), female (F). Location: frontal (F), temporal (T), parietal (P), occipital (O), corpus callosum (CC). Treatment: radiotherapy (RT), chemotherapy (CH). Survival: all cases are exitus except (*) that were alive at the end of the present study and (?) that are cases with unknown evolution. (na): non-available. EGFRwt: EGFR wild type, EGFRvIII: EGFR mutant.